PIXY321 data

IMNX reported on a Phase I/II trial in pediatric patients receiving ICE (ifosfamide/carboplatin/etoposide) chemotherapy. PIXY was administered at three dose levels, 500, 750 or 1000 µg/m2/day to 16 patients with refractory solid tumors and 6 patients with solid tumors for which there is no standard treatment.

The drug was well tolerated and the maximum tolerated dose hasn't been reached, investigators said. Most common side effects were low grade fever and local reactions. Two patients left the study due to chest pain; and generalized flushing and tachycardia. ...